# Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients

> **NCT00745914** · NA · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 22 (actual)

## Conditions studied

- Endstage Renal Disease
- Diabetes

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT00745914
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2013-09
- **Final completion:** 2013-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00745914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00745914, "Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00745914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*